2211 GMT - Sigma Healthcare is already showing early benefits from its merger with Chemist Warehouse, and Jefferies is optimistic that the good news will continue. Sigma upgraded its FY 2025 guidance for normalized Ebit to A$64 million-A$70 million, from a prior target of A$50 million-A$60 million. Jefferies expects A$67.2 million. "We believe margin expansion within Sigma can continue," says analyst David Stanton. Jefferies lifts its price target on Sigma by 4.9% to A$2.15/share, although that's below the current stock price of A$2.92 and the key reason why the bank stays at underperform. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 09, 2025 17:11 ET (22:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.